|
ASTHMA: New Phase III data show tiotropium * Respimat ® effective across …
Business Wire (press release) Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities. These data were presented at … |
View full post on asthma – Google News